

Composition : Amlodipine + Olmesartan; (5mg+20mg) & (5mg+40mg) Tablet

Indications : This combination drug is indicated for the treatment of hypertension, alone or with other antihypertensive agents. This fixed combination drug is not indicated for the initial therapy of hypertension.

Dosage and administration : The usual starting dose of Disartan is 5/20mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum dose of 10/40mg once daily as needed to control blood pressure. Maximum antihypertensive effects are attained within 2 weeks after a change in dose. Or, as directed by the registered physician.

Side effects : The side effects of this drug are generally related to those of each of its components. The most common side effects include: edema, dizziness, flushing and palpitation. Other side effects are asthenia, angioedema, pruritus, urticaria, alopecia, vomiting, rhabdomyolysis, acute renal failure, jaundice, hepatic enzyme elevations.

Contraindication : There is no evidence of contraindications.

Use in pregnancy and lactation : When used in pregnancy during the second and third trimesters, drugs that act directly on the rennin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, this drug should be discontinued as soon as possible.

Drug interactions : No significant drug interactions were reported in studies in which amlodipine was co-administered with digoxin, phenytoin, warfarin, cimetidine,

Disartan

Film Coated Tablet

atorvastatin and indomethacin. No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin, warfarin and antacids. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes and thus interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected.

Precautions : Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Symptomatic hypotension may occur after initiation of treatment with olmesartan. Caution should be exercised when administering the drug, particularly in patients with severe aortic stenosis. Calcium channel blockers should be used with caution in patients with heart failure. Treatment with this drug associated with oliguria or progressive azotemia and (rarely) with acute renal failure and/or death. Caution should be exercised when administering this drug to patients with severe hepatic impairment.

Packing : Disartan : 2x14's tablets in blister pack.

Disartan 5/40 : 2x14's tablets in blister pack.